| [1] |
Faria B, Canao P, Cai Q, et al. Arteriolar C4d in IgA nephropathy: a cohort study [J]. Am J Kidney Dis, 2020, 76(5): 669-678.
|
| [2] |
Yu GZ, Guo L, Dong JF, et al. Persistent hematuria and kidney disease progression in IgA nephropathy: a cohort study [J]. Am J Kidney Dis, 2020, 76(1): 90-99.
|
| [3] |
Rehnberg J, Symreng A, Ludvigsson JF, et al. Inflammatory bowel disease is more common in patients with IgA nephropathy and predicts progression of ESKD: a Swedish population-based cohort study [J]. J Am Soc Nephrol, 2020, Epub ahead of print.
|
| [4] |
Rauen T, Wied S, Fitzner C, et al. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy [J]. Kidney Int, 2020, 98(4): 1044-1052.
|
| [5] |
Barbour SJ, Canney M, Coppo R, et al. Improving treatment decisions using personalized risk assessment from the international IgA nephropathy prediction tool [J]. Kidney Int, 2020, 98(4): 1009-1019.
|
| [6] |
Zhang J, Huang B, Liu Z, et al. External validation of the international IgA nephropathy prediction tool [J]. Clin J Am Soc Nephrol, 2020, 15(8): 1112-1120.
|
| [7] |
Sethi S, Debiec H, Madden B, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy [J]. Kidney Int, 2020, 97(1): 163-174.
|
| [8] |
Sethi S, Debiec H, Madden B, et al. Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients [J]. Kidney Int, 2020, 98(5): 1253-1264.
|
| [9] |
Xie J, Liu L, Mladkova N, et al. The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis [J]. Nat Commun, 2020, 11(1): 1600.
|
| [10] |
Reinhard L, Zahner G, Menzel S, et al. Clinical relevance of domain-specific phospholipase A2 receptor 1 antibody levels in patients with membranous nephropathy [J]. J Am Soc Nephrol, 2020, 31(1): 197-207.
|
| [11] |
Fernandez-Juarez G, Rojas-Rivera J, Logt AV, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy [J]. Kidney Int, 2020, Epub ahead of print.
|
| [12] |
Doria A, Galecki AT, Spino C, et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes [J]. N Engl J Med, 2020, 382(26): 2493-2503.
|
| [13] |
Cannon CP, Perkovic V, Agarwal R, et al. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%: results from the CREDENCE trial [J]. Circulation, 2020, 141(5): 407-410.
|
| [14] |
Oshima M, Neuen BL, Jardine MJ, et al. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial [J]. Lancet Diabetes Endocrinol, 2020, 8(11): 903-914.
|
| [15] |
Tofte N, Lindhardt M, Adamova K, et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial [J]. Lancet Diabetes Endocrinol, 2020, 8(4): 301-312.
|
| [16] |
Malvar A, Alberton V, Lococo B, et al. Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis [J]. Kidney Int, 2020, 97(1): 156-162.
|
| [17] |
Mok CC, Ho LY, Ying SKY, et al. Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis [J]. Ann Rheum Dis, 2020, 79(8): 1070-1076.
|
| [18] |
Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis [J]. N Engl J Med, 2020, 383(12): 1117-1128.
|
| [19] |
Atisha-Fregoso Y, Malkiel S, Harris KM, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis [J]. Arthritis Rheumatol, 2020, Epub ahead of print.
|
| [20] |
Casal Moura M, Irazabal MV, Eirin A, et al. Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe kidney disease [J]. J Am Soc Nephrol, 2020, 31(11): 2688-2704.
|
| [21] |
Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis [J]. N Engl J Med, 2020, 382(7): 622-631.
|
| [22] |
Charles P, Perrodeau E, Samson M, et al. Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial [J]. Ann Intern Med, 2020, 173(3): 179-187.
|
| [23] |
Yu XJ, Zhang X, Li DY, et al. Renal pathologic spectrum and clinical outcome of monoclonal gammopathy of renal significance: a large retrospective case series study from a single institute in China [J]. Nephrology (Carlton), 2020, 25(3): 202-211.
|
| [24] |
Nasr SH, Larsen CP, Sirac C, et al. Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone [J]. Kidney Int, 2020, 97(3): 589-601.
|
| [25] |
Royal V, Leung N, Troyanov S, et al. Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study [J]. Blood, 2020, 135(21): 1833-1846.
|
| [26] |
Yadav P, Sathick IJ, Leung N, et al. Serum free light chain level at diagnosis in myeloma cast nephropathy-a multicentre study [J]. Blood Cancer J, 2020, 10(3): 28.
|
| [27] |
Song J, Jiang F, Liu H, et al. Effect factors related to a high probability of hemodialysis independence in newly diagnosed multiple myeloma patients requiring hemodialysis [J]. J Clin Lab Anal, 2020, 34(2): e23057.
|
| [28] |
Kumar SK, Jacobus SJ, Cohen AD, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial [J]. Lancet Oncol, 2020, 21(10): 1317-1330.
|
| [29] |
Ball S, Behera TR, Anwer F, et al. Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials [J]. Ann Hematol, 2020, 99(6): 1265-1271.
|
| [30] |
Roussel M, Merlini G, Chevret S, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis [J]. Blood, 2020, 135(18): 1531-1540.
|
| [31] |
Gabarre P, Dumas G, Dupont T, et al. Acute kidney injury in critically ill patients with COVID-19 [J]. Intensive Care Med, 2020, 46(7): 1339-1348.
|
| [32] |
Bowe B, Cai M, Xie Y, et al. Acute kidney injury in a national cohort of hospitalized US veterans with COVID-19 [J]. Clin J Am Soc Nephrol, 2020, 16(1): 14-25.
|
| [33] |
Wald R, Bagshaw SM. COVID-19-associated acute kidney injury: learning from the first wave [J]. J Am Soc Nephrol, 2020, 32(1): 4-6.
|
| [34] |
Kolhe NV, Fluck RJ, Selby NM, et al. Acute kidney injury associated with COVID-19: a retrospective cohort study [J]. PLoS Med, 2020, 17(10): e1003406.
|
| [35] |
Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19 [J]. Kidney Int, 2020, 97(5): 829-838.
|
| [36] |
中华医学会肾脏病学分会专家组. 新型冠状病毒感染合并急性肾损伤诊治专家共识[J]. 中华肾脏病杂志，2020, 36(3): 242-246.
|
| [37] |
Nadim MK, Forni LG, Mehta RL, et al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup [J]. Nat Rev Nephrol, 2020, 16(12): 747-764.
|
| [38] |
Brar S, Liu KD, Go AS, et al. Prospective cohort study of renin-angiotensin system blocker usage after hospitalized acute kidney injury [J]. Clin J Am Soc Nephrol, 2020, 16(1): 26-36.
|
| [39] |
Secora AM, Shin JI, Qiao Y, et al. Hyperkalemia and acute kidney injury with spironolactone use among patients with heart failure [J]. Mayo Clin Proc, 2020, 95(11): 2408-2419.
|
| [40] |
Collaborative S. Perioperative nonsteroidal anti-inflammatory drugs (NSAID) administration and acute kidney injury (AKI) in major gastrointestinal surgery: a prospective, multicenter, propensity matched cohort study [J]. Ann Surg, 2020, Epub ahead of print.
|
| [41] |
Rampersad C, Kraut E, Whitlock RH, et al. Acute kidney injury events in patients with type 2 diabetes using SGLT2 inhibitors versus other glucose-lowering drugs: a retrospective cohort study [J]. Am J Kidney Dis, 2020, 76(4): 471-479.
|
| [42] |
Magee DE, Hird AE, Klaassen Z, et al. Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials [J]. Ann Oncol, 2020, 31(1): 50-60.
|
| [43] |
Gutgarts V, Jain T, Zheng J, et al. Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery [J]. Biol Blood Marrow Transplant, 2020, 26(6): 1071-1076.
|
| [44] |
Gupta S, Seethapathy H, Strohbehn IA, et al. Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor t-cell (CAR-T) therapy for diffuse large B-cell lymphoma [J]. Am J Kidney Dis, 2020, 76(1): 63-71.
|
| [45] |
Lee MD, Strohbehn IA, Seethapathy HS, et al. Acute kidney injury after the CAR-T therapy tisagenlecleucel [J]. Am J Kidney Dis, 2020, Epub ahead of print.
|
| [46] |
Weisbord SD, Palevsky PM, Kaufman JS, et al. Contrast-associated acute kidney injury and serious adverse outcomes following angiography [J]. J Am Coll Cardiol, 2020, 75(11): 1311-1320.
|
| [47] |
Itano Y, Kato S, Tsuboi M, et al. A prospective, randomized clinical trial of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism (the DUET trial) [J]. Kidney Int Rep, 2020, 5(12): 2168-2177.
|
| [48] |
Djuric P, Dimkovic N, Schlieper G, et al. Sodium thiosulphate and progression of vascular calcification in end-stage renal disease patients: a double-blind, randomized, placebo-controlled study [J]. Nephrol Dial Transplant, 2020, 35(1): 162-169.
|
| [49] |
Raggi P, Bellasi A, Sinha S, et al. Effects of SNF472, a novel inhibitor of hydroxyapatite crystallization in patients receiving hemodialysis-subgroup analyses of the CALIPSO trial [J]. Kidney Int Rep, 2020, 5(12): 2178-2182.
|